ProCE Banner Activity

Advances in B-Cell Lymphomas: Understanding Current Treatment Approaches

Podcast Episodes
In this podcast episode, listen to Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, discuss current and emerging treatment approaches for patients with B-cell lymphomas from a recent satellite symposium at the annual Hematology meeting in 2021.

Released: February 25, 2022

Expiration: February 24, 2023

Share

Faculty

Brad S. Kahl

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

John P. Leonard

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Atara Biotherapeutics

Bayer Healthcare Pharma

BeiGene, Ltd.

Epizyme

Genentech, a member of the Roche Group

Genmab US, Inc.

Incyte Corporation

Karyopharm Therapeutics

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Faculty Disclosure

Primary Author

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Brad S. Kahl, MD, has disclosed that he has received funds for research support from AbbVie, ADCT, AstraZeneca, BeiGene, and Genentech and consulting fees from AbbVie, Adaptive, ADCT, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Incyte, Janssen, Karyopharm, Kite, MEI, Pharmacyclics, Roche, and Teva.

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York

John P. Leonard, MD, has disclosed that he has received funds for research support from Genentech and consulting fees from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb/Celgene, Epizyme, Genentech/Roche, Genmab, Gilead Sciences/Kite, Incyte, Janssen, Karyopharm, MEI Pharma, Miltenyi, Regeneron, and Sutro.

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA, has disclosed that she has received funds for research support from Acerta/AstraZeneca, Celgene/Bristol-Myers Squibb, Epizyme, Incyte, Kite, Loxo, Novartis, and Seattle Genetics and consulting fees from AbbVie, Acerta/AstraZeneca, Conjupro, Janssen/Pharmacyclics, Johnson & Johnson, Kite, Morphosis, Oncternal, Roche/Genentech, and Vaniam Group.

Additional Information

Program Medium

This program has been made available online.